Cevimeline · oral capsule
Dry Eye/OSD
Approved uses
Dry mouth in Sjögren's syndrome
30 mg orally three times daily; there is insufficient safety information to support doses above 30 mg three times daily
Contraindicated in narrow angles and acute iritis, which is the reason an eye examination belongs before it is started
Contraindications
- Uncontrolled asthma
- Known hypersensitivity to cevimeline
- When miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle-closure) glaucoma
Cevimeline hydrochloride 30 mg capsules, in child resistant bottles of 100 capsules
Cevimeline is a cholinergic agonist which binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands, and increase tone of the smooth muscle in the gastrointestinal and urinary tracts.
Warnings & Precautions
- Cardiac conduction and heart rate changes: Cevimeline can potentially alter cardiac conduction and/or heart rate, and patients with significant cardiovascular disease may potentially be unable to compensate for transient changes in hemodynamics or rhythm; use with caution and under close medical supervision in patients with a history of cardiovascular disease evidenced by angina pectoris or myocardial infarction.
- Increased airway resistance: Cevimeline can potentially increase airway resistance, bronchial smooth muscle tone, and bronchial secretions; administer with caution and with close medical supervision to patients with controlled asthma, chronic bronchitis, or chronic obstructive pulmonary disease.
- Visual blurring: Ophthalmic formulations of muscarinic agonists have been reported to cause visual blurring, which may result in decreased visual acuity, especially at night and in patients with central lens changes, and to cause impairment of depth perception; advise caution while driving at night or performing hazardous activities in reduced lighting.
- Exaggerated parasympathomimetic effects: Cevimeline toxicity is characterized by an exaggeration of its parasympathomimetic effects, which may include headache, visual disturbance, lacrimation, sweating, respiratory distress, gastrointestinal spasm, nausea, vomiting, diarrhea, atrioventricular block, tachycardia, bradycardia, hypotension, hypertension, shock, mental confusion, cardiac arrhythmia, and tremors.
- Biliary obstruction and renal colic: Administer with caution to patients with a history of nephrolithiasis or cholelithiasis; contractions of the gallbladder or biliary smooth muscle could precipitate complications such as cholecystitis, cholangitis and biliary obstruction, and increased ureteral smooth muscle tone could theoretically precipitate renal colic or ureteral reflux in patients with nephrolithiasis.
- Dehydration: If a patient sweats excessively while taking cevimeline, dehydration may develop; the patient should drink extra water and consult a health care provider.
- Conduction disturbances: Administer with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.
- Additive effects: Drugs with parasympathomimetic effects given concurrently can be expected to have additive effects, and cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly.
- Higher risk of adverse events: Drugs which inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline; use with caution in individuals known or suspected to be deficient in CYP2D6 activity, as they may be at a higher risk of adverse events.
Common Side Effects
Adverse events associated with muscarinic agonism at 30 mg tid (n=533) versus placebo (n=164) included excessive sweating (18.7% vs 2.4%), nausea (13.8% vs 7.9%), rhinitis (11.2% vs 5.4%), and diarrhea (10.3% vs 10.3%). Other adverse events reported at 3% or more included headache (14.4% vs 20.1% on placebo), sinusitis (12.3%), upper respiratory tract infection (11.4%), dyspepsia (7.8%), and abdominal pain (7.6%). In the U.S. placebo-controlled Sjögren's studies, 320 patients received cevimeline 15 mg tid to 60 mg tid, and 14.6% of patients discontinued treatment due to adverse events.
Pregnancy: Cevimeline was associated with a reduction in the mean number of implantations in pregnant rats at 45 mg/kg/day (approximately 5 times the maximum recommended dose for a 60 kg human), an effect that may have been secondary to maternal toxicity. There are no adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether this drug is secreted in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness in pediatric patients have not been established.